Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

396
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
396
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

294
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
294
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.

Pediatric rheumatology online journal·2026
Same author

NK cell dysfunction and interferon-γ production underlie autoinflammation in mevalonate kinase deficiency.

Immunity·2026
Same author

Single-cell profiling of BAL in preschool cystic fibrosis reveals macrophage dysregulation and ivacaftor-modified inflammatory programs in the early life lung.

Mucosal immunology·2026
Same author

Comparative performance of common paediatric patient-reported outcome measures (P-PROMs) across health conditions.

Archives of disease in childhood·2026
Same author

Macrophages orchestrate antiviral defense and epithelial repair in a human iPSC-derived alveolar air-liquid interface.

JCI insight·2026
Same author

Antibody responses against bacterial glycans affinity mature and diversify in germinal centers.

Immunity·2026

Related Experiment Video

Updated: Jul 1, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

749

Eosinophilia and wheeze: thinking beyond asthma.

Stephanie L Kuek1, Colin Pettman2, Melanie R Neeland3,4

  • 1Respiratory and Sleep Medicine, Royal Children's Hospital, Melbourne, Australia.

Breathe (Sheffield, England)
|March 14, 2024
PubMed
Summary

Primary idiopathic hypereosinophilic syndrome is a rare disorder causing organ damage. Mepolizumab offers a safe, effective treatment, reducing the need for steroids.

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.1K

Related Experiment Videos

Last Updated: Jul 1, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

749
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.1K

Area of Science:

  • Hematology
  • Immunology
  • Rare Diseases

Background:

  • Primary idiopathic hypereosinophilic syndrome (HES) is a rare clonal disorder.
  • It is characterized by sustained eosinophilia and potential end-organ damage.
  • Current treatments often involve corticosteroids with significant side effects.

Observation:

  • Patients with HES experience damage across multiple organ systems.
  • Eosinophil proliferation drives the pathology in HES.
  • Steroid-dependent treatments carry substantial long-term risks.

Findings:

  • Targeted monoclonal antibodies, specifically mepolizumab, demonstrate efficacy in HES.
  • Mepolizumab targets interleukin-5 (IL-5), a key cytokine in eosinophil development.
  • This targeted therapy provides a steroid-sparing alternative.

Implications:

  • Mepolizumab offers a safer and effective treatment option for HES.
  • Reduced reliance on corticosteroids can mitigate treatment-related toxicities.
  • Targeted therapies represent a significant advancement in managing rare eosinophilic disorders.